ClinicalTrials.gg

Program

desoxyepothilone B

Also written as “Utidelone Capsule”, “Utidelone” and “Utidelone in combination with capecitabine”.

Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Brain Neoplasms · Lung Neoplasms, led by 4 companies.

Furthest: phase 3, since Sep 29, 201419 company-led studies, 9 open or runningNext primary completion: Dec 1, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Biostar Pharmaceuticals138 open or runningphase 3since Sep 29, 2014Sep 29, 2014Dec 1, 2026phase 2 · NCT06683703
Bristol-Myers Squibb30 open or runningphase 2since Apr 5, 2004Feb 7, 2002none ahead
Biostar Pharma21 open or runningphase 2since Jan 7, 2025Dec 30, 2022Jan 15, 2027phase 2 · NCT06764940
Hoffmann-La Roche10 open or runningphase 2since Jun 15, 2006Jun 15, 2006none ahead

Also a collaborator on its studies: chengdu-biostar-pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Feb 7, 2002.

  1. Jun 15, 2006Hoffmann-La Roche's first study: phase 2 study in Breast NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT00337649 · 27 enrolled · Spain
  2. Sep 29, 2014Beijing Biostar Pharmaceuticals's first study: phase 3 study in Breast NeoplasmsNew to Beijing Biostar PharmaceuticalsBeijing Biostar Pharmaceuticals · NCT02253459 · 405 enrolled · China
  3. Sep 29, 2018Phase 2 study in Advanced Non-small Cell Lung CancerBeijing Biostar Pharmaceuticals · NCT03693547 · 26 enrolled · China
  4. Apr 5, 2019Phase 2 study in Advanced or Metastatic CRCBeijing Biostar Pharmaceuticals · NCT03906565 · 30 enrolled · China
  5. May 30, 2021Phase 1 study in Breast NeoplasmsBeijing Biostar Pharmaceuticals · NCT05052437 · 16 enrolled · China
  6. May 30, 2021Phase 2 study in Solid TumorBeijing Biostar Pharmaceuticals · NCT04911907 · 126 enrolled · China
  7. Dec 30, 2022Phase 2 study in Advanced Solid TumorBeijing Biostar Pharmaceuticals · NCT05700084 · 84 enrolled · China
  8. Dec 30, 2022Biostar Pharma's first study: phase 1 study in Advanced Solid TumorNew to Biostar PharmaBiostar Pharma · NCT05681000 · 28 enrolled · United States
  9. Dec 30, 20222 phase 3 studiesBeijing Biostar Pharmaceuticals · NCT05673629, NCT05673590
  10. Nov 6, 20242 phase 2 studiesBeijing Biostar Pharmaceuticals · NCT06683703, NCT06730581
  11. Jan 7, 2025Phase 2 study in Breast NeoplasmsBiostar Pharma · NCT06764940 · 120 planned · United States
  12. Feb 10, 2025Phase 3 study in Gastric or Gastroesophageal Junction AdenocarcinomaBeijing Biostar Pharmaceuticals · NCT06841679 · 778 planned · United States, China
  13. Jun 23, 2025Phase 2 study in Ovarian NeoplasmsBeijing Biostar Pharmaceuticals · NCT07044349 · 72 planned
  14. Jun 29, 2026Phase 3 study in Advanced Breast CancerBeijing Biostar Pharmaceuticals · NCT07684456 · 308 planned · China

Ahead

  1. Dec 1, 2026Primary completion: phase 2 study in Non-small Cell Lung Cancer Patients with Brain MetastasesBeijing Biostar Pharmaceuticals · NCT06683703
  2. Dec 31, 2026Primary completion: phase 2 study in Ovarian NeoplasmsBeijing Biostar Pharmaceuticals · NCT06730581
  3. Jan 15, 2027Primary completion: phase 2 study in Breast NeoplasmsBiostar Pharma · NCT06764940
  4. Mar 2027Primary completion: phase 2 study in Ovarian NeoplasmsBeijing Biostar Pharmaceuticals · NCT07044349

TargetBeta

“Tubulin stabiliser”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
PaclitaxelruleHoffmann-La Rochephase 4202
DocetaxelruleSanofiphase 4199
cabazitaxelruleSanofiphase 421
VinblastineruleTakedaphase 44
plinabulinrulebeyondspring-pharmaceuticals-incphase 38

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07684456Advanced Breast Cancer · China3Not yet recruitingBeijing Biostar PharmaceuticalsMar 1, 2028308
NCT07044349Ovarian Neoplasms2Not yet recruitingBeijing Biostar PharmaceuticalsMar 202772
NCT06841679Gastric or Gastroesophageal Junction Adenocarcinoma · United States, China3RecruitingBeijing Biostar PharmaceuticalsSep 1, 2030778
NCT06764940Breast Neoplasms · United States2RecruitingBiostar PharmaJan 15, 2027120
NCT06730581Ovarian Neoplasms2Not yet recruitingBeijing Biostar PharmaceuticalsDec 31, 2026100
NCT06683703Non-small Cell Lung Cancer Patients with Brain Metastases2Not yet recruitingBeijing Biostar PharmaceuticalsDec 1, 2026118
NCT05700084Advanced Solid Tumor · China2Active, not recruitingBeijing Biostar PharmaceuticalsOct 8, 202584
NCT05681000Advanced Solid Tumor · United States1UNKNOWNBiostar PharmaApr 15, 202428
NCT05673629Breast Neoplasms · China3RecruitingBeijing Biostar PharmaceuticalsJun 15, 2025552
NCT05673590Carcinoma, Non-Small-Cell Lung · China3RecruitingBeijing Biostar PharmaceuticalsJun 15, 2025612
NCT05052437Breast Neoplasms · China1CompletedBeijing Biostar PharmaceuticalsJan 13, 202116
NCT04911907Solid Tumor · China2CompletedBeijing Biostar PharmaceuticalsMay 31, 2025126
NCT03906565Advanced or Metastatic CRC · China2SuspendedBeijing Biostar PharmaceuticalsDec 31, 202330
NCT03693547Advanced Non-small Cell Lung Cancer · China2CompletedBeijing Biostar PharmaceuticalsJun 25, 202126
NCT02253459Breast Neoplasms · China3CompletedBeijing Biostar PharmaceuticalsSep 2016405
NCT00337649Breast Neoplasms · Spain2CompletedHoffmann-La RocheJul 200727
NCT00104130Prostatic Neoplasms · United States2TerminatedBristol-Myers Squibb53
NCT00080509Lung Neoplasms2TerminatedBristol-Myers Squibb85
NCT00030173Neoplasms · United States1CompletedBristol-Myers Squibb45

How it is read

Names in the registry

  • “Utidelone Capsule”, 7 entries
  • “Utidelone”, 3 entries
  • “Utidelone in combination with capecitabine”, 3 entries
  • “utidelone injection”, 3 entries
  • “Utidelone combined with Bevacizumab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.